



**Limited Review Report on Unaudited financial results of M/s Vineet Laboratories Limited**

Independent Auditor's Report on Quarterly and Year to Date Unaudited financial Results of M/s VINEET LABORATORIES LIMITED pursuant to regulation 33 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015.

**TO THE BOARD OF DIRECTORS OF Vineet Laboratories Limited**

We have reviewed the accompanying unaudited financial results of **M/s Vineet Laboratories Limited**, for the quarter ended 31 December 2023 and for the period from 1 April 2023 to 31 December 2023. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standards on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the entity' issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free from material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.

The procedures performed in a review are substantially less than those performed in an audit conducted in accordance with Standards on Auditing. Accordingly, we do not express an audit opinion on these financial results. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and that it contains any material misstatement.

Based on our review, nothing has come to our attention that causes us to believe that these financial statements do not give a true and fair view of the financial position of **M/s Vineet Laboratories Limited** as at 31 December 2023.

For NSVR & Associates LLP  
Chartered Accountants  
FRN: 008801S/S200060

*V. Gangadhara*

V Gangadhara Rao  
Partner

M. No.219486

UDIN: 24219486BKFAXD3754

Place: Hyderabad

Date: 12-02-2024.



**VINEET LABORATORIES LIMITED**  
CIN:L24304TG2016PLC112888

SY. No. 11/A3, Eshwaramma Nilayam, Saheb Nagar, Kurdu Vill, Chintal Kunta, LB Nagar, Hyderabad, Telangana-500074, India.

**Statement of Unaudited Financial Results for the quarter and Nine Months ended 31 December 2023**

(All Amounts in Indian rupees lakhs, except share data and where otherwise stated)

S No	Particulars	Quarter ended			9 Months ended		Year ended
		31 December 2023	30 September 2023	31 December 2022	31 December 2023	31 December 2022	31 March 2023
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	a) Net Sales/income from operations	3,264.70	4,337.27	6,676.47	11,354.27	15,509.18	21,229.33
II	b) Other income	1.25	1.44	0.18	5.24	8.92	12.30
III	<b>Total Income (I + II)</b>	<b>3,265.95</b>	<b>4,338.71</b>	<b>6,676.65</b>	<b>11,359.51</b>	<b>15,518.10</b>	<b>21,241.63</b>
VI	<b>Expenses</b>						
	a) Cost of material consumed	2,978.16	3,174.85	5,011.37	9,183.32	12,526.70	16,809.76
	b) Changes in inventories of finished goods, work-in progress and stock-in-trade(increase)/decrease	(348.28)	(131.37)	911.99	(431.42)	618.63	423.03
	c) Employee benefits expense	176.65	139.65	202.00	456.54	447.62	600.29
	d) Finance costs	107.68	102.46	103.09	306.02	301.06	338.02
	e) Depreciation and amortisation expenses	62.65	61.20	50.80	184.71	175.47	237.26
	f) Other expenses	522.32	737.49	355.92	1,767.36	1,730.79	2,630.28
	<b>Total expenses</b>	<b>3,499.18</b>	<b>4,084.27</b>	<b>6,635.17</b>	<b>11,466.53</b>	<b>15,800.27</b>	<b>21,038.64</b>
V	<b>Profit/(loss) before exceptional items and tax (III - IV)</b>	<b>(233.23)</b>	<b>254.44</b>	<b>41.48</b>	<b>(107.02)</b>	<b>(282.17)</b>	<b>202.99</b>
VI	Exceptional itmes	-	-	-	-	-	-
VII	<b>Profit/(loss) before Tax (V -VI)</b>	<b>(233.23)</b>	<b>254.44</b>	<b>41.48</b>	<b>(107.02)</b>	<b>(282.17)</b>	<b>202.99</b>
VIII	<b>Tax expense :</b>						
	a. Current tax	(29.19)	10.48	(23.99)	(18.71)	(23.99)	56.02
	b. Deferred tax	2.54	2.06	(73.81)	1.37	(28.68)	21.72
IX	<b>Profit/(loss) for the period (VII-VIII)</b>	<b>(206.58)</b>	<b>241.90</b>	<b>139.28</b>	<b>(89.68)</b>	<b>(229.51)</b>	<b>125.25</b>
X	<b>Other comprehensive income(OCI)</b>						
	A.						
	(i) Items that will not be reclassified subsequently to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified subsequently to profit or loss	-	-	-	-	-	-
	B.						
	(i) Items that will be reclassified subsequently to profit or loss	-	-	-	-	-	17.99
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	(4.53)
	<b>Total other comprehensive income</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>13.46</b>
XI	<b>Total comprehensive income for the Period (IX+X)</b>	<b>(206.58)</b>	<b>241.90</b>	<b>139.28</b>	<b>(89.68)</b>	<b>(229.51)</b>	<b>138.71</b>
XII	<b>Paid-up Equity Share capital (Face Value of Rs. 10/- per share)</b>	<b>921.90</b>	<b>921.90</b>	<b>921.90</b>	<b>921.90</b>	<b>921.90</b>	<b>921.90</b>
XIII	<b>Other Equity</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>2,446.45</b>
XIV	<b>Earnings per equity share (of Rs. 10/- each) (not annualised for the quarters)</b>						
	(i) Basic	(2.24)	2.62	1.51	(0.97)	(2.49)	1.36
	(ii) Diluted.	(2.24)	2.62	1.51	(0.97)	(2.49)	1.36

**Notes**

- The above unaudited financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act 2013 with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India.
- The above unaudited results has been reviewed and recommended by Audit Committee and approved by the Board of Directors at their meetings held on 12th February 2024.
- The Statutory Auditors of the Company have carried out the limited review of the above unaudited financial results and their report has been placed before the board at the said meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015.
- The company operates in one reportable business segment i.e. Active pharmaceuticals ingredient and intermediates. Hence segment reporting as per Ind AS 108 is not applicable.
- The results for the quarter and nine months ended 31 December 2023 are also available on website of BSE Limited, NSE Limited and on the Company's website.
- Figures for the previous periods have been rearranged/ reclassified wherever necessary to conform to the current period presentation.

Date: 12-02-2024.  
Place: Hyderabad.



For and on Behalf of Board of Directors

*Bh. Satyanarayana Raju*  
Bh. Satyanarayana Raju  
Whole time Director & CFO  
DIN:02697880




**VINEET LABORATORIES LIMITED**  
**CIN:L24304TG2016PLC112888**

Regd Office : SY . No. 11/A3, Saheb nagar, Kurdu Vill, Chintal Kunta, Eshwaramma Nilayam, L B Nagar, Hyderabad, Telangana-500074, India.  
Un-Audited Statement of Profit and Loss and Other Comprehensive Income for the Year ended 31st December 2023

Particulars	NoteNo.	For the period ended Dec 2023	For the year ended March 31, 2023
<b>Continuing Operations</b>			
I Revenue from operations	20	1,13,54,26,704	2,12,29,33,046
II Other income	21	5,24,224	12,30,137
<b>III Total income</b>		<b>1,13,59,50,928</b>	<b>2,12,41,63,183</b>
<b>IV Expenses</b>			
(a) Cost of material Consumed	23	91,83,32,424	1,68,09,76,077
(b) Purchase of Stock in Trade			
(c) Changes in stock of finished goods, work-in progress and stock-in-trade	24	(4,31,42,264)	4,23,03,019
(d) Employee benefits	25	4,56,54,245	6,00,29,343
(e) Finance cost	26	3,06,02,076	3,38,01,876
(f) Depreciation expense	27	1,84,70,721	2,37,26,002
(g) Other expenses	28	17,67,35,936	26,30,27,653
<b>Total expenses (IV)</b>		<b>1,14,66,53,138</b>	<b>2,10,38,63,970</b>
<b>Profit/(loss) before Share of profit/(loss) of associates / joint ventures, exceptional items and tax (V - VI)</b>		<b>(1,07,02,210)</b>	<b>2,02,99,213</b>
<b>VI Profit/(Loss) before exceptional items and tax</b>		<b>(1,07,02,210)</b>	<b>2,02,99,213</b>
<b>VIII Exceptional itmes</b>		-	-
<b>IX Profit before Tax</b>		<b>(1,07,02,210)</b>	<b>2,02,99,213</b>
<b>X Tax expense :</b>			
a. Current tax		(18,71,354)	56,01,754
b. Deferred tax		1,37,013	21,72,005
Total			
<b>XI Profit/(loss) for the year from continuing operations (XI-XII)</b>		<b>(89,67,869)</b>	<b>1,25,25,454</b>
<b>Discontinued Operations</b>			
XII Profit/(loss) from discontinued operations		-	-
XIII Tax Expense of discontinued operations		-	-
<b>XIV Profit/(loss) from discontinued operations (XIV +XV)</b>		<b>-</b>	<b>-</b>
<b>XV XVII Profit/(loss) for the year (XIII+XVI)</b>		<b>(89,67,869)</b>	<b>1,25,25,454</b>
<b>XVI Other comprehensive income(OCI)</b>			
A (i) Items that will not be reclassified to profit or loss			
Re-measurement gains/ (losses) on defined benefit plans		-	17,98,982
Income tax effect relating to above item		-	(4,52,804)
B (i) Items that may be reclassified to profit or loss		-	-
(ii) Income tax on items that may be reclassified to profit or loss		-	-
<b>Total other comprehensive income</b>		<b>-</b>	<b>13,46,178</b>
<b>XVII Total comprehensive income for the year (V+ VI)</b>		<b>(89,67,869)</b>	<b>1,38,71,632</b>
<b>XVIII Earning per equity share (for Continuing Opertations)</b>			
(i) Basic		-0.97	1.36
(ii) Diluted.		-0.97	1.36
<b>XIX Earnings per equity share (for discontinued operation):</b>			
(i) Basic		0	0
(ii) Diluted.		0	0
<b>XX Earnings per equity share (for Continued and discontinued operation):</b>			
(i) Basic		-0.97	1.36
(ii) Diluted.		-0.97	1.36

The notes are an integral part of the financial statements



**For and on behalf of the Board of Directors**  
**VINEET LABORATORIES LIMITED**

BH.Satyanarayana Raju  
Whole Time Director & CFO  
DIN .02697880

Place: Hyderabad  
Date: 12.02.2024